Tamoxifen-induced hypercalcemia in breast cancer

摘要: Among 470 patients with metastatic breast cancer treated tamoxifen, ten (2.3%) developed hypercalcemia. All hypercalcemia had osteolytic or mixed lytic and blastic bone metastases. Hypercalcemia after a median period of seven days (range 4-11 days) tamoxifen administration. was conventional measures serum calcium levels normalized in nine patients, either brief interruption therapy spite continued treatment. Four experienced partial remissions therapy. These results indicate that is potentially serious complication but generally short-lived, can be controlled supportive measures, thus allowing